Top Story

Urine gene expression assay may noninvasively diagnose prostate cancer

May 31, 2016

Read the Perspective from Donald L. Trump, MD, FACP

A novel urine exosome gene expression assay added to standard-of-care assessments improved the identification of high-grade prostate cancers among men with elevated PSA levels, according to the results of a prospective study.

“The test has the potential to be a significant improvement over PSA alone in distinguishing between low- and high-grade prostate cancer, especially in the PSA gray zone patient,” James McKiernan, MD, John K. Lattimer professor and chair of urology at Columbia University Medical Center, said in a press release. “It could reduce hundreds of thousands of invasive biopsies each year.”

In the Journals

Temsirolimus demonstrates short-lived activity in primary CNS lymphoma

May 31, 2016
Temsirolimus monotherapy exhibited clinical activity in patients with relapsed and refractory primary central nervous system lymphoma, although most responses were short…
In the Journals

Triplet chemotherapy may benefit intermediate-, poor-risk germ cell tumors

May 31, 2016
A chemotherapeutic triplet comprised of paclitaxel, ifosfamide and cisplatin exhibited efficacy as first-line treatment for patients with intermediate- or poor-risk germ…

Does chemotherapy cause cancer?

May 31, 2016
Patients with cancer who undergo chemotherapy may be at elevated risk for a new primary cancer several years later.The most common secondary cancers that occur in…
In the Journals

TP53 status may predict response to VEGFR inhibition for advanced sarcoma

May 31, 2016
The TP53 gene mutation may predict improved response to VEGF receptor inhibition among patients with advanced sarcomas, according to a retrospective chart review.Prior…
More News Headlines »
CME Video

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this…
More »
Meeting News Coverage

VIDEO: Expert discusses controversies in lung cancer screenings

May 13, 2016
More »
AACR Annual Meeting

AACR Annual Meeting


NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan morganatic-roan